226 related articles for article (PubMed ID: 23350812)
1. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.
Grosset KA; Malek N; Morgan F; Grosset DG
Eur J Neurol; 2013 Nov; 20(11):1445-50. PubMed ID: 23350812
[TBL] [Abstract][Full Text] [Related]
2. Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging study.
Grosset KA; Malek N; Morgan F; Grosset DG
Acta Neurol Scand; 2013 Sep; 128(3):166-71. PubMed ID: 23527823
[TBL] [Abstract][Full Text] [Related]
3. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
Grosset KA; Malek N; Morgan F; Grosset DG
J Parkinsons Dis; 2013; 3(1):31-7. PubMed ID: 23938309
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
7. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
8. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction.
Von Keitz AT; Ströberg P; Bukofzer S; Mallard N; Hibberd M
BJU Int; 2002 Mar; 89(4):409-15. PubMed ID: 11872034
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Lockhart D; Staines H; Lees A
Parkinsonism Relat Disord; 2021 Feb; 83():79-85. PubMed ID: 33486139
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study.
Nomoto M; Kubo S; Nagai M; Yamada T; Tamaoka A; Tsuboi Y; Hattori N;
Clin Neuropharmacol; 2015; 38(6):241-7. PubMed ID: 26536022
[TBL] [Abstract][Full Text] [Related]
11. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
van Laar T; Jansen EN; Essink AW; Neef C; Oosterloo S; Roos RA
Clin Neurol Neurosurg; 1993 Sep; 95(3):231-5. PubMed ID: 8242966
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
Nicholas AP; Borgohain R; Chaná P; Surmann E; Thompson EL; Bauer L; Whitesides J; Elmer LW;
J Parkinsons Dis; 2014; 4(3):361-73. PubMed ID: 24643203
[TBL] [Abstract][Full Text] [Related]
13. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.
Ostergaard L; Werdelin L; Odin P; Lindvall O; Dupont E; Christensen PB; Boisen E; Jensen NB; Ingwersen SH; Schmiegelow M
J Neurol Neurosurg Psychiatry; 1995 Jun; 58(6):681-7. PubMed ID: 7608665
[TBL] [Abstract][Full Text] [Related]
14. Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study.
Tan EK; Ratnagopal P; Han SY; Wong MC
Acta Neurol Scand; 2003 Mar; 107(3):202-6. PubMed ID: 12614313
[TBL] [Abstract][Full Text] [Related]
15. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
16. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.
LeWitt PA; Pahwa R; Sedkov A; Corbin A; Batycky R; Murck H
J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):155-161. PubMed ID: 29161531
[TBL] [Abstract][Full Text] [Related]
18. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings.
Riley A; Main M; Morgan F
J Sex Med; 2010 Apr; 7(4 Pt 1):1508-17. PubMed ID: 19845547
[TBL] [Abstract][Full Text] [Related]
19. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
Rascol O; Azulay JP; Blin O; Bonnet AM; Brefel-Courbon C; Césaro P; Damier P; Debilly B; Durif F; Galitzky M; Grouin JM; Pennaforte S; Villafane G; Yaici S; Agid Y
Mov Disord; 2010 Feb; 25(3):368-76. PubMed ID: 20063435
[TBL] [Abstract][Full Text] [Related]
20. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
Factor SA
Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]